Meet Ultima Genomics at EACR 2026
Our team will be attending EACR 2026, where we would love to talk to you about our ultra high‑throughput whole‑genome sequencing and ppmSeq™ minimal residual disease (MRD) detection, and how these methods are redefining what’s possible in cancer genomics. From accelerating large‑scale studies to enabling earlier, more precise detection of recurrence, Ultima is delivering the power, speed, and resolution researchers need to unlock the next breakthroughs in cancer science.
Meet with us at EACR
Contact us to request an in person meeting at EACR with Kevin Dunne, our General Manager in EMEA, and Gilad Almogy, our CEO.
Request a meeting